Cambria Investment Management L.P. Makes New $700,000 Investment in Abbott Laboratories $ABT

Cambria Investment Management L.P. purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 3rd quarter, Holdings Channel reports. The fund purchased 5,226 shares of the healthcare product maker’s stock, valued at approximately $700,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after acquiring an additional 2,977,715 shares in the last quarter. State Street Corp increased its position in Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after buying an additional 689,517 shares in the last quarter. Geode Capital Management LLC boosted its stake in Abbott Laboratories by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after purchasing an additional 1,390,554 shares in the last quarter. Norges Bank purchased a new stake in shares of Abbott Laboratories during the second quarter valued at $3,026,180,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Abbott Laboratories by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after purchasing an additional 821,325 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $113.09 on Thursday. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.15. The business has a 50-day simple moving average of $116.67 and a 200-day simple moving average of $124.91. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The company has a market cap of $196.51 billion, a PE ratio of 30.40, a P/E/G ratio of 1.81 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the previous year, the business earned $1.34 EPS. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is 67.74%.

Insider Activity

In other Abbott Laboratories news, EVP Elizabeth C. Cushman sold 263 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $30,397.54. Following the completion of the transaction, the executive vice president owned 38,573 shares in the company, valued at approximately $4,458,267.34. This represents a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Piper Sandler lowered their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Daiwa Securities Group reduced their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. The Goldman Sachs Group cut their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Finally, Leerink Partners reduced their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $137.05.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA approved Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader that could improve clinician workflows and patient adoption, supporting long‑term device revenue growth. How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Several insiders (senior VPs/EVPs) disclosed small sales of ABT shares on Mar. 2 — amounts are modest relative to their remaining holdings and likely represent routine portfolio management rather than a clear signal. Abbott Laboratories Insider Selling
• Neutral Sentiment: Elevated investor attention — Zacks flags ABT as drawing interest, which can amplify moves in either direction but doesn’t by itself change fundamentals. Abbott Laboratories (ABT) is Attracting Investor Attention
• Negative Sentiment: Revenue miss in the latest quarter (reported $11.46B vs. consensus ≈ $11.8B) — EPS met estimates but the top‑line shortfall and softer near‑term trends have left analysts cautious and pressured the stock. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Legal risk: Abbott is set to face trial over claims that a premature‑infant formula caused a deadly disease — a high‑visibility lawsuit that could create financial and reputational downside depending on outcomes or settlements. Abbott set to face trial over claims premature infant formula caused deadly disease

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.